GRTX · Galera Therapeutics, Inc.

This filing communicates procedural governance milestones tied to the Combined 2025 and 2026 Annual Meeting, reflecting a scheduling adjustment necessitated by the meeting occurring more than 60 days after the February 24, 2025 anniversary date. The April 13, 2026 deadline serves dual functions: it satisfies the advance notice requirements under the Company’s Amended and Restated Bylaws for director nominations and stockholder proposals, and it aligns with SEC Rule 14a-19’s universal proxy mandate for dissident nominees. While no voting results or proposals are disclosed here, the firm deadline directly impacts shareholder engagement strategy, particularly for activist investors or nominating stockholders seeking board representation or agenda items. The absence of substantive voting outcomes or contested proposals means this is primarily an administrative disclosure; however, the consolidation of two annual meetings into one may signal operational streamlining or reflect strategic considerations around corporate governance cadence. Investors should monitor whether any proposals or nominations are subsequently submitted and disclosed in future filings.